Education
About Us
Working with TipRanks
Follow Us
Acurx Pharmaceuticals (DE:3ZO)
FRANKFURT:3ZO
RESEARCH TOOLSreports
3ZO Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.56 - €2.62
Previous CloseN/A
Volume0.00
Average Volume (3M)1.67K
Market Cap
$8.24M
Enterprise Value€25.33M
Total Cash (Recent Filing)-$2.48M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-1.01
Next Earnings
Mar 18, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,533,745
10 Day Avg. Volume4,800
30 Day Avg. Volume1,667
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap3.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.19
Forecast
1Y Price Target
€11.07Price Target Upside1809.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsIbezapolstat demonstrated a high clinical cure rate of 96% in Phase 2 studies, indicating strong efficacy for treating C. difficile Infection.
Regulatory ApprovalAlignment with a second major regulatory agency was a key milestone, confirming that the clinical, non-clinical, and CMC data package sufficiently supports ibezapolstat's entry into a Phase 3 program for treating C. difficile Infection in the EU.
Bears Say
Investment RisksRisks to the investment thesis and target price include failure or equivocal data in the Phase 3 trials of ibezapolstat.
---
Options Prices
Currently, No data available
---
Ownership Overview
12.19% Insiders
3.36% Mutual Funds
2.01% Other Institutional Investors
79.57% Public Companies and Individual Investors
3ZO FAQ
What was Acurx Pharmaceuticals’s price range in the past 12 months?
Acurx Pharmaceuticals lowest stock price was €0.56 and its highest was €2.62 in the past 12 months.
What is Acurx Pharmaceuticals’s market cap?
Acurx Pharmaceuticals’s market cap is $8.24M.
When is Acurx Pharmaceuticals’s upcoming earnings report date?
Acurx Pharmaceuticals’s upcoming earnings report date is Mar 18, 2025 which is in 8 days.
How were Acurx Pharmaceuticals’s earnings last quarter?
Acurx Pharmaceuticals released its earnings results on Nov 13, 2024. The company reported -€0.157 earnings per share for the quarter, missing the consensus estimate of -€0.134 by -€0.023.
Is Acurx Pharmaceuticals overvalued?
According to Wall Street analysts Acurx Pharmaceuticals’s price is currently Undervalued.
Does Acurx Pharmaceuticals pay dividends?
Acurx Pharmaceuticals does not currently pay dividends.
What is Acurx Pharmaceuticals’s EPS estimate?
Acurx Pharmaceuticals’s EPS estimate is -0.16.
How many shares outstanding does Acurx Pharmaceuticals have?
Acurx Pharmaceuticals has 19,533,745 shares outstanding.
What happened to Acurx Pharmaceuticals’s price movement after its last earnings report?
Acurx Pharmaceuticals reported an EPS of -€0.157 in its last earnings report, missing expectations of -€0.134. Following the earnings report the stock price went up 1.056%.
Which hedge fund is a major shareholder of Acurx Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:3ZO
---
Company Description
Acurx Pharmaceuticals
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention, and Food and Drug Administration.
---
3ZO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and regulatory readiness, which are promising for future developments. However, financial challenges and the need for funding to proceed with Phase III trials pose risks.Read More>---
3ZO Stock 12 Month Forecast
Average Price Target
€11.07
▲(1809.25% Upside)
Technical Analysis
Best Analysts Covering 3ZO
1 Year
1 Year Success Rate
4/18 ratings generated profit
1 Year Average Return
-37.46%
reiterated a buy rating 2 months ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -37.46% per trade.
---